The AFFINITY Study: Seeking 20 FSGS Patients

Published on August 15, 2023

The AFFINITY study is a global, open-label, phase 2 basket trial evaluating the safety and efficacy of atrasentan, an endothelin receptor antagonist, in patients with proteinuric glomerular diseases including IgA nephropathy, Alport syndrome, diabetic kidney disease and FSGS.

Continue reading on website
Other news

Advocating with Congress for Rare Kidney Disease

July 25, 2023
I spent July 12 on Capitol Hill in Washington DC, logging over 4 miles as I walked between 3 buildings to talk about rare kidney disease with the offices of eight senators and representatives. Thank you to our partners at NephCure for organizing this Rare Kidneys on the Hill Day. It was an inspiring and positive experience, especially as we learned that several of the lawmakers and legislative ass

Addressing the Unequal Burden of Kidney Disease on Black Americans

August 18, 2023
As kidney specialists, I'm sure we all know the statistic that chronic kidney disease is a worldwide epidemic, with 1 in 7 adults in the US affected by CKD and one third of the population at risk. However, Black and African Americans are disproportionally impacted by chronic kidney disease and have higher rates of kidney failure: though comprising 13% of the US population, Black and African Americ